美国食品药品监督管理局批准了Jardiance (empagliflozin)治疗2型糖尿病的药品，用于降低病人由糖尿病引起的心血管疾病并死亡的危险。

　　“在成年人中2型糖尿病是引起心血管疾病导致死亡的诱因，这种治疗2型糖尿病的药物是一项重要的革新，可以降低由其引起的心血管疾病而导致死亡的风险。”FDA药品评估中心的研究人员如是说。

　　疾病与预防控制中心称，同时患有心脑血管疾病和糖尿病的成年人比只患有心脑血管疾病的人死亡率高70%，这些同时患有两种疾病的患者的生命往往终结于心脑血管疾病的爆发，这使患者的寿命缩短。经7000患者的实验表明，Jardiance在同期对比实验中对于治疗2型糖尿病并心血管疾病具有显著疗效。

　　实验显示Jardiance最常见的副作用就是尿路感染和女性的生殖器感染。

　　The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease.

　　“Cardiovascular disease is a leading cause of death in adults with type 2 diabetes mellitus,” said Jean-Marc Guettier, M.D., C.M., director of the Division of Metabolism and Endocrinology Products in FDA’s Center for Drug Evaluation and Research. “Availability of antidiabetes therapies that can help people live longer by reducing the risk of cardiovascular death is an important advance for adults with type 2 diabetes.”

　　According to the Centers for Disease Control and Prevention, death from cardiovascular disease is 70 percent higher in adults with diabetes compared to those without diabetes, and patients with diabetes have a decreased life expectancy driven in large part by premature cardiovascular death.

　　The most common side effects of Jardiance are urinary tract infections and female genital infections.